Bristol Myers Squibb (BMY) EBT Margin Growth (3y) (2012 - 2026)
Powered by 
Analysis
Bristol Myers Squibb (BMY) EBT Margin Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | -265.00 |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 636.00 |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 3,137.00 |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 625.00 |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | -2,179.00 |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 1,494.00 |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | -977.00 |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 8,006.00 |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | 1,581.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1,494.00 |
| Mar 31, 2026 | 377.00 |
| Dec 31, 2025 | -454.00 |
| Sep 30, 2025 | 579.00 |
| Jun 30, 2025 | -202.00 |
| Mar 31, 2025 | 1,204.00 |
| Dec 31, 2024 | -1,408.00 |
| Sep 30, 2024 | -446.00 |
| Jun 30, 2024 | -273.00 |
| Mar 31, 2024 | -11,991.00 |
| Dec 31, 2023 | 10,901.00 |
| Sep 30, 2023 | -193.00 |
| Jun 30, 2023 | 50.00 |
| Mar 31, 2023 | 2,725.00 |
| Dec 31, 2022 | 1,792.00 |
| Sep 30, 2022 | -277.00 |
| Jun 30, 2022 | -1,184.00 |
| Mar 31, 2022 | -1,895.00 |
| Dec 31, 2021 | -969.00 |
| Sep 30, 2021 | -1,952.00 |